Abstract
The kinase oncogenes are well-characterized drivers of cancer development, and several targeted therapies focused on both specific and selectively nonselective kinase inhibitors have now been approved for clinical use. In contrast, much less is known about the role of protein phosphatases, although modulation of their activities might form the foundation for an effective anti-cancer approach. The serine-threonine protein phosphatase 2A (PP2A) is implicated in the regulation of numerous signaling pathways and may function as a tumor suppressor. Recently pharmacological modulation of PP2A activity has been showed to have a potent anti-tumor activity in both in vitro and in vivo cancer models. These studies implicate PP2A as a promising therapeutic target for the treatment of cancer.
Keywords: Protein phosphatase 2A, Drug Development, Cancer, CIP2A, FTY720, Forskolin, Norcantharidin derivatives, Cantharidin, kinase, PP2A, CML
Anti-Cancer Agents in Medicinal Chemistry
Title: Protein Phosphatase 2A as a Potential Target for Anticancer Therapy
Volume: 11 Issue: 1
Author(s): Peter Kalev and Anna A. Sablina
Affiliation:
Keywords: Protein phosphatase 2A, Drug Development, Cancer, CIP2A, FTY720, Forskolin, Norcantharidin derivatives, Cantharidin, kinase, PP2A, CML
Abstract: The kinase oncogenes are well-characterized drivers of cancer development, and several targeted therapies focused on both specific and selectively nonselective kinase inhibitors have now been approved for clinical use. In contrast, much less is known about the role of protein phosphatases, although modulation of their activities might form the foundation for an effective anti-cancer approach. The serine-threonine protein phosphatase 2A (PP2A) is implicated in the regulation of numerous signaling pathways and may function as a tumor suppressor. Recently pharmacological modulation of PP2A activity has been showed to have a potent anti-tumor activity in both in vitro and in vivo cancer models. These studies implicate PP2A as a promising therapeutic target for the treatment of cancer.
Export Options
About this article
Cite this article as:
Kalev Peter and A. Sablina Anna, Protein Phosphatase 2A as a Potential Target for Anticancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941172
DOI https://dx.doi.org/10.2174/187152011794941172 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of the Non-Specific Binding Proteins in the RNA Pull-Down Experiment
Current Proteomics Editorial: (Thematic Issue: Occupational Exposure: An Undermined Risk Factor of Lung Diseases in the Informal Sectors of Developing Economy)
Current Respiratory Medicine Reviews MicroRNAs and Physical Activity
MicroRNA The Role of Zebrafish in Chemical Genetics
Current Medicinal Chemistry Nanocarriers for the Effective Treatment of Cervical Cancer: Research Advancements and Patent Analysis
Recent Patents on Drug Delivery & Formulation Chemically Synthesized Matrix Metalloproteinase and Angiogenesis-inhibiting Peptides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies
Current Cancer Drug Targets “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets MiR-597 Targeting 14-3-3σ Enhances Cellular Invasion and EMT in Nasopharyngeal Carcinoma Cells
Current Molecular Pharmacology Prediction of Bioactive Compound Pathways Using Chemical Interaction and Structural Information
Combinatorial Chemistry & High Throughput Screening Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Novel Nicotinonitrile Derivatives Bearing Imino Moieties Enhance Apoptosis and Inhibit Tyrosine Kinase
Anti-Cancer Agents in Medicinal Chemistry Peptides, Proteins and Peptide/Protein-Polymer Conjugates as Drug Delivery System
Protein & Peptide Letters Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry Sirtuins: Novel Players in Male Reproductive Health
Current Medicinal Chemistry